Bertram Wiedenmann, MD, PhD of Charité Universitätsmedizin Berlin? discusses the NETTER-1 results for patients with neuroendocrine tumors received an 18% response rate. Here is more details about the trial background: Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 (177Lu)Dotatate in patients with advanced, progressive, somatostatin-receptorpositive midgut neuroendocrine tumors.
NETTER-1 Results patients with neuroendocrine tumors 18% response rate
